Gilead Company Profile

✉ Email this page to a colleague

GILEAD has thirty approved drugs.

There are eighty-eight US patents protecting GILEAD drugs.

There are two thousand three hundred and twenty-three patent family members on GILEAD drugs in sixty-six countries and three hundred and ninety-seven supplementary protection certificates in nineteen countries.

International Patents:	2323
US Patents:	88
Tradenames:	24
Ingredients:	24
NDAs:	30
Patent Litigation for Gilead:	See patent lawsuits for Gilead
PTAB Cases with Gilead as patent owner:	See PTAB cases with Gilead as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead	EMTRIVA	emtricitabine	SOLUTION;ORAL	021896-001	Sep 28, 2005		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-001	Jul 23, 2014		RX	Yes	No	9,149,477	⤷ Try a Trial				⤷ Try a Trial
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-001	Jun 15, 2007	AB	RX	Yes	No	9,474,752	⤷ Try a Trial				⤷ Try a Trial
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-002	Jun 10, 2021		RX	Yes	Yes	7,964,580*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	8,754,065*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Gilead Sciences Inc	SOVALDI	sofosbuvir	PELLETS;ORAL	212480-002	Aug 28, 2019		RX	Yes	Yes	8,889,159*PED	⤷ Try a Trial			Y	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-002	Mar 10, 2016	6,642,245*PED	⤷ Try a Trial
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-001	Oct 26, 2001	4,808,716	⤷ Try a Trial
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-002	Jun 15, 2007	7,601,730	⤷ Try a Trial
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004	6,642,245*PED	⤷ Try a Trial
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	6,838,464	⤷ Try a Trial
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	POWDER;ORAL	022577-001	Jan 18, 2012	5,977,089*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2015-12-09
➤ Subscribe	Tablets	10 mg	➤ Subscribe	2010-06-08
➤ Subscribe	Tablets	200 mg/300 mg	➤ Subscribe	2008-09-26
➤ Subscribe	Tablets	600 mg/200 mg/300 mg	➤ Subscribe	2008-12-29
➤ Subscribe	Tablets	150 mg, 200 mg, and 250 mg	➤ Subscribe	2012-05-17
➤ Subscribe	Tablets	150 mg, 150 mg, 200 mg, 300 mg	➤ Subscribe	2018-10-04
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2012-07-16
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2015-02-09
➤ Subscribe	Tablets	100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg	➤ Subscribe	2017-05-19
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2010-01-26
➤ Subscribe	Tablets	200 mg/25 mg/300 mg	➤ Subscribe	2015-05-20

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1419152	PA2012008	Lithuania	⤷ Try a Trial	PRODUCT NAME: RILPIVIRINUM; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
3347352	55/2022	Austria	⤷ Try a Trial	PRODUCT NAME: LENACAPAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON, INSBESONDERE LENACAPAVIR-NATRIUM; REGISTRATION NO/DATE: EU/1/22/1671 (MITTEILUNG) 20220819
1419152	CA 2012 00021	Denmark	⤷ Try a Trial
0915894	C00915894/02	Switzerland	⤷ Try a Trial	PRODUCT NAME: TENOFOVIRDISOPROXIL + EFAVIRENZ + EMTRICITABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 60011 20.11.2009
1761540	C20170009 00226	Estonia	⤷ Try a Trial	PRODUCT NAME: IDELALISIIB;REG NO/DATE: EU/1/14/938 19.09.2014
1663240	CA 2016 00063	Denmark	⤷ Try a Trial	PRODUCT NAME: RILPIVIRIN ELLER TERAPEUTISK AEKVIVALENT FORM DERAF BESKYTTET AF GRUNDPATENTET SASOM ET FARMACEUTISK ACCEPTABELT SALT FX HYDROCHLORIDSALTET AF RILPIVIRIN OG TENOFOVIRALAFENAMID ELLER FARMACEUTISK ACCEPTABELT SALT DERAF FX TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.